Hyrnuo Sevabertinib
Hyrnuo (sevabertinib) is an oral targeted therapy used to treat adults with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) that has HER2 (ERBB2) tyrosine kinase domain activating mutations. It is prescribed after patients have received at least one prior systemic therapy. Hyrnuo works by blocking HER2-driven tumor growth and is taken twice […]
Jascayd-Nerandomilast
Jascayd is an orally administered small-molecule therapy indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. It works by inhibiting multiple fibrotic and inflammatory signaling pathways involved in lung tissue scarring, thereby slowing disease progression and preserving pulmonary function. Through targeted modulation of fibroblast activity and reduction of extracellular matrix deposition, Jascayd helps […]
Lynkuet-Elinzanetant
Lynkuet is the first and only dual neurokinin 1 and 3 (NK1/NK3) receptor antagonist approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. By blocking NK1 and NK3 receptor signaling in the hypothalamic thermoregulatory center, Lynkuet helps reduce the frequency and severity of hot flashes, both during the day and at […]
Kygevvi-Doxecitine And Doxribtimine
Kygevvi is the first FDA-approved oral therapy for the treatment of Thymidine Kinase 2 Deficiency (TK2d) in adults and pediatric patients with symptom onset at 12 years of age or younger. TK2d is a rare, genetic mitochondrial disorder that leads to progressive muscle weakness and respiratory complications. Kygevvi works by replenishing deoxynucleoside levels to help […]
Wayrilz-Rilzabrutinib
Wayrilz is an oral reversible BTK inhibitor indicated for adults with chronic immune thrombocytopenia (ITP). It works by modulating immune pathways to increase platelet counts and reduce the risk of bleeding, offering a convenient twice-daily oral treatment option.
Forzinity-Elamipretide
Forzinity is a mitochondrial-targeted therapy for Barth syndrome in patients weighing 30 kg or more. It stabilizes mitochondrial function to improve energy production and muscle strength, administered via subcutaneous injection.
Inluriyo-Imlunestrant
Inluriyo is an oral selective estrogen receptor degrader (SERD) indicated for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. It degrades estrogen receptors to block tumor growth, offering a convenient daily oral option.
Palsonify-Paltusotine
Palsonify is an oral somatostatin receptor agonist approved for adults with acromegaly. It suppresses excess growth hormone and IGF-1 levels, providing a once-daily, non-injectable alternative to traditional therapies.
Rhapsido-Remibrutinib
Rhapsido is an oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). By blocking mast cell activation and histamine release, it effectively reduces hives and itch in patients unresponsive to antihistamines.
Qalsody-Tofersen
Qalsody is the first FDA‑approved antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations. It reduces SOD1 protein synthesis by targeting SOD1 mRNA, addressing disease progression at a genetic level.
